Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141791 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Etanercept in Moderate to Severe Asthma
A Phase 2 study of Asthma, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 13
- Study locations
NCT00141791: Completed Phase 2 study of Asthma, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00141791 is a Phase 2 study of Asthma that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 120 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141791, a Phase 2 study of Asthma, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.
Conditions Studied
Interventions
- DRUG Etanercept
Study Locations (13)
Florida
- - Sarasota
- - Tallahassee
- - Valrico
Alabama
- - Birmingham
Colorado
- - Denver
Louisiana
- - Covington
Maryland
- - Wheaton
Massachusetts
- - Boston
New York
- - Rockville Centre
North Carolina
- - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
What the finished NCT00141791 record still lists
NCT00141791 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Etanercept is the first listed.
NCT00141791 lists 13 locations in 11 states (Florida, Alabama, Colorado).
Frequently Asked Questions
What is clinical trial NCT00141791 about?
NCT00141791 is a clinical study titled "Study Evaluating Etanercept in Moderate to Severe Asthma". The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.
What is the current status of trial NCT00141791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2005-05. Estimated completion is 2006-07.
What conditions does trial NCT00141791 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00141791?
The interventions under investigation include: Etanercept (DRUG).
Who is sponsoring clinical trial NCT00141791?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141791 being conducted?
This trial has 13 study locations across Alabama, Colorado, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00141791's enrollment target sits among peer trials
120 199th of 374 higher than 175 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia